Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Accessing in-depth insights from the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report will help you:

  • Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market.
  • Analyze the clinical and commercial landscapes of each indication, with pricing assumptions
  • Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy
  • Identify the Likelihood of Approval Analysis for the most promising agents and Phase Transition Success Rate Analysis.
  • Identify key future players based on their Pipeline Strength.

How is the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report different from other reports in the market?

  • It highlights the major key regions (APAC, Europe, Middle East, and North America) in the ALL cell & gene therapies market.
  • The report provides in-depth qualitative coverage of potential countries (US, France, Germany, Italy, Spain, Belgium, Canada, UK, Japan, and China) with high potential for cell and gene therapies.
  • It provides deep insights into the target patient pool, clinical-stage pipeline, and autologous and allogeneic cell therapies.
  • It provides information on sales forecast extrapolations, which leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.
  • The report offers rich competitive intelligence content, such as competitors, needs, and opportunities which will help in making important business decisions on time.

We recommend this valuable source of information to anyone involved in:

  • Pharmaceutical companies
  • Biotech
  • CMOs, CMOs, CDMOs
  • Consulting Companies
  • Professional Services (e.g., Investment, Equity Companies, Banks)

To get a snapshot of the Acute Lymphocytic Leukemia Cell Therapy market report, Download a Free Report Sample

Acute Lymphocytic Leukemia Cell Therapy Market Overview

The Acute Lymphocytic Leukemia Cell Therapy market value for the 15 markets (15M) was $2.3 billion in 2021. This included both cell therapies and established/traditional ALL therapies. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada.

The Acute Lymphocytic Leukemia Cell Therapy market research report includes an assessment of the disease epidemiology and a 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) for marketed and pipeline therapies with established mechanisms of action by class, including early to late clinical-stage pipeline products, with a launch date assessment by the market for acute lymphocytic leukemia (ALL).

Acute Lymphocytic Leukemia Cell Therapy Market Drivers and Unmet Needs

Established CAR-T therapies to grow market share via label expansions: Kymriah is expected to move into 1L, and Tecartus is expected to achieve a label for the pediatric patient population. The inability to find a donor for stem cell transplants drives the need for stem cell replacement products such as NiCord and TRGFT-201.

Agents for T-ALL and infant ALL are one of the unmet needs of the ALL market. Patients with T-ALL have perhaps the highest unmet need with no biologics available. CAR-Ts present a promising strategy to overcome this unmet need. Pipeline anti-CD7 CGT and non-CGT agents are being developed to treat T-ALL patients.

To know more about the drivers in the Acute Lymphocytic Leukemia Cell Therapy Market, download a free report sample

Acute Lymphocytic Leukemia Cell Therapy Market Segmentation by Regions

The key regions in the Acute Lymphocytic Leukemia Cell Therapy market are North America, APAC, Europe, and the Middle East. North America had the highest share in 2021.

Acute Lymphocytic Leukemia Cell Therapy Market Analysis by Regions, 2021 (%)

ALL Market Analysis by Regions

For more regional insights on the Acute Lymphocytic Leukemia market, download a free report sample

Acute Lymphocytic Leukemia Cell Therapy Market - Competitive Landscape

Some of the future players in the Acute Lymphocytic Leukemia Cell Therapy Market are Hebei Senlang Biotechnology, Chongqing Precision Biotech, Sian Wuhan Medical Technology Co Ltd, Novartis AG, iCell Gene Therapeutics LLC, and Wugen Inc among others. Hebei Senlang Biotechnology and Chongqing Precision Biotech are the leading sponsors of cell therapy trials in the ALL market.

Acute Lymphocytic Leukemia Cell Therapy Market Report Overview

Market Size (2021 in 15M) $2.3 billion
Key Regions North America, APAC, Europe, and The Middle East
Future Players Hebei Senlang Biotechnology, Chongqing Precision Biotech, Sian Wuhan Medical Technology Co Ltd, Novartis AG, iCell Gene Therapeutics LLC, and Wugen Inc

Reasons to Buy

  • Obtain cell therapy sales forecasts across multiple regions

  • Gain insight into promising early stage approaches

  • Our indication specific forecast models answer questions such as:

  • What is the target patient pool for cell & gene therapies in each cancer indication?

  • Which patient groups are more likely to receive these therapies?

  • What does the cell & gene therapy clinical stage pipeline look like in each cancer indication

  • What is the anticipated breakdown between autologous and allogeneic cell therapies?

  • When will cell & gene therapies launch in each market?

  • What is the total market value projected for the forecast end, in 2031?

  • Novartis

  • Gilead

  • Autolus Therapeutics

  • Gamida Cell

  • Orca Biosystems

  • Coimmune

  • Cellectis

  • Juventas Cell Therapy

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. Etiology & Epidemiology

3.2. ALL Treatment Algorithm

4. Pipeline Drugs Overview

4.1. Pipeline Analysis

4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

8.1. Competitive Analysis by Class of Therapy

9. Future Players

9.1. Future Players Based on Pipeline Strength

10. Appendix

10.1. Cell Therapies Forecast Methodology Overview

10.2. Pricing of Cell Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 in real time.

  • Access a live Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.